Company chief Dilip Shanghvi, known for his midas touch in the pharma industry, has for years stayed away from biosimilars but now aims to spend between 8-9 percent of turnover on RD.from Moneycontrol Business News https://ift.tt/3wJyg6H
Company chief Dilip Shanghvi, known for his midas touch in the pharma industry, has for years stayed away from biosimilars but now aims to spend between 8-9 percent of turnover on RD.
Comments
Post a Comment